Genmab-developed sclerosis treatment beats competition in small injector pen study
Following the approval of sclerosis drug Kesimpta, originally from Genmab, Novartis is positioning this drug against its competitors. New study shows patients' and health personnel's impression of the firm's special injector pen compared with treatments from Teva, Biogen and Merck.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Novartis has, in a recent study, examined sclerosis patients' impressions of the firm's autoinjector pens used to administer its medication.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab and Seagen submit cancer drug application to US FDA
For subscribers
